Alkermes (ALKS) PT Lowered to $45 at BofA/Merrill Lynch; Sees Loss in 2015
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Alkermes plc (ALKS) Phase 1 Study of ALKS 7106 Fails, Further Development Halted
February 24, 2015 7:05 AM ESTAlkermes plc (NASDAQ: ALKS) today announced topline results from a phase 1 clinical study of ALKS 7106, a new molecule intended for the treatment of pain. The randomized, double-blind, placebo-controlled study was designed to evaluate the safety, tolerability and pharmacokinetics of single escalating doses of ALKS 7106 in 64 healthy adults. Data from the study showed that ALKS 7106 did not meet... More
Alkermes plc (ALKS) Tops Q4 EPS by 7c; Guides FY15
February 24, 2015 7:03 AM ESTAlkermes plc (NASDAQ: ALKS) reported Q4 EPS of $0.11, $0.07 better than the analyst estimate of $0.04. Revenue for the quarter came in at $175.2 million versus the consensus estimate of $161.7 million.
Alkermes plc sees FY2015 EPS of $0.27-$0.40, versus the consensus of $0.20. Alkermes plc sees FY2015... More
